A study conducted at the Research Institute of the McGill University Health Centre (RI-MUHC) suggests screening breast cancer patients for the prolactin receptor could improve the prognosis for patients and may help them avoid unnecessary and invasive treatments. Using a database of 580 women with triple negative breast cancer (TNBC), the researchers found that survival was prolonged in patients who expressed the prolactin receptor and that prolactin hormone was able to reduce the aggressive behavior of cancerous cells. It does so by decreasing their ability to divide and form new tumors.
By Julie Robert, McGill University Health Centre Canadian researchers describe the first outbreak of Cryptosporidium parasite in Nunavik
By Julie Robert, McGill University Health Centre A research team, led by the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal, has broken new ground in our understanding of the complex functioning of the brain.
It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre (RI-MUHC) and University of Alberta could be a game changer for patients, improving both quality of life and longevity. The research team discovered a new gene involved in muscle wasting that could be a good target for drug development.
In a large study analyzing 20 years of data from Quebec, a team from the Research Institute of the McGill University Health Centre (RI-MUHC) has demonstrated that gestational diabetes signals future diabetes risk not only in mothers, but also in fathers. The study was recently published in Diabetes Care.
Research from McGill University suggests that people who are vulnerable to developing alcoholism exhibit a distinctive brain response when drinking alcohol, according to a new study by Prof. Marco Leyton, of McGill University’s Department of Psychiatry. Compared to people at low risk for alcohol-use problems, those at high risk showed a greater dopamine response in a brain pathway that increases desire for rewards. These findings, published in the journal Alcoholism: Clinical & Experimental Research, could help shed light on why some people are more at risk of suffering from alcoholism and could mark an important step toward the development of treatment options.
Recent technological developments in genomics have revealed a large number of genetic influences on common complex diseases, such as diabetes, asthma, cancer or schizophrenia. However, discovering a genetic variant predisposing to a disease is only a first step. To apply this knowledge towards prevention or cure, including tailoring treatment to the patient’s genetic profile –also known as personalized medicine – we need to know how this genetic variant affects health.